Bruce Feinberg, DO; Brian Kiss, MD; and Ted Okon, MBA, describe changes in healthcare such as the shift in focus toward more patient-centric medicine, consideration of patient-reported outcomes, the implementation of the 340B Drug Pricing Program, and the consolidation of the healthcare industry. The managed care stakeholders also discuss innovation in oncology and their concerns about how the growth in the utilization of oral oncolytics affects community practices.
As a better understanding is gained of the human genome and molecular pathways that play a role in certain types of cancers, explains Dr Feinberg, the development of oral oncolytics that target specific molecular pathways has expanded.
Oral treatment options currently comprise 25 to 35 percent of the drug pipeline, adds Mr Okon. An oral chemotherapy drug is often as expensive as or more expensive than the infusible form. As these new options become integrated into treatment recommendations, providers are beginning to recognize trends that affect patient adherence and outcomes.
Mr Okon remarks that the Community Oncology Alliance has researched patient adherence in relation to the costs of therapy and adds that providers need to ensure that patients fill their prescriptions at the pharmacy following their medical appointments.
In the past, when drugs were infused in a clinical setting by a healthcare professional, Mr Okon explains, providers could be reasonably certain that patients would receive their treatment as prescribed. The use of oral oncolytics complicates the monitoring of adherence within community practices because providers need to ensure that their patients recognize the benefits of taking a drug as prescribed and fill their prescriptions.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More